Skip to main
AMPH
AMPH logo

Amphastar Pharma (AMPH) Stock Forecast & Price Target

Amphastar Pharma (AMPH) Analyst Ratings

Based on 6 analyst ratings
Hold
Strong Buy 17%
Buy 17%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Amphastar Pharmaceuticals Inc. has demonstrated strong sales momentum, particularly with Baqsimi, which experienced approximately a 20% quarter-over-quarter increase in prescriptions during the third quarter of 2025, supported by strategic collaborations and seasonal demand. The company is projected to achieve a return to double-digit growth in 2026, following a flat year-over-year topline in 2025, indicating solid recovery potential. Additionally, Primatene Mist's robust performance signals further revenue growth opportunities, enhancing the optimistic outlook on Amphastar's market position and valuation relative to its peers.

Bears say

Amphastar Pharmaceuticals Inc. is facing significant challenges that are likely to negatively impact its financial outlook, particularly due to increased competition in key product segments such as iron sucrose and glucagon, which are expected to generate sales much lower than previously anticipated. Specifically, projected annual sales for iron sucrose have been reduced from an expected $60 million to around $20 million, while glucagon sales are expected to drop below $70 million starting in 2026 due to intensified market competition. Additionally, the anticipated return to double-digit top-line growth in 2026 has been tempered to a range of high-single digits to low-double digits, reflecting concerns about the company's growth pipeline.

Amphastar Pharma (AMPH) has been analyzed by 6 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 17% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amphastar Pharma (AMPH) Forecast

Analysts have given Amphastar Pharma (AMPH) a Hold based on their latest research and market trends.

According to 6 analysts, Amphastar Pharma (AMPH) has a Hold consensus rating as of Dec 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amphastar Pharma (AMPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.